English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We report the cloning and characterization of thegyrA gene of theMycoplasma hominis DNA gyrase, which was previously shown to be associated with quinolone resistance in this organism. The 2,733-bpgyrA gene encodes a protein of 911 amino acids with a calculated molecular mass of 102.5 kDa. As expected,M. hominis GyrA exhibits higher homology with the GyrA subunits of the gram-positive bacteriaClostridium acetobutylicum ,Bacillus subtilis ,Streptococcus pneumoniae , andStaphylococcus aureus than with itsEscherichia coli counterpart. Knowing the entire sequence of thegyrA gene ofM. hominis could be very useful for confirming the role of the GyrA subunit in fluoroquinolone resistance. Twenty-nine mutants ofM. hominis were selected stepwise for resistance to trovafloxacin, a new potent fluoroquinolone, and theirgyrA ,gyrB ,parC , andparE quinolone resistance-determining regions were characterized. Three rounds of selection yielded 3 first-step, 12 second-step, and 14 third-step mutants. The first-step mutants harbored a single substitution, Glu460→Lys (E. coli coordinates), in ParE. GyrA changes, Ser83→Leu, Glu87→Lys, and Ala119→Glu or Val, were found only in the second round of selection. At the third step, additional substitutions, at ParC Ser80, Ser81, and Glu84 and ParE Leu440, associated with high-level resistance to fluoroquinolones, appeared. Thus, high-level resistance to trovafloxacin required three steps and was associated with alterations in both fluoroquinolone targets. According to these genetic data, inM. hominis , as inStaphylococcus aureus andStreptococcus pneumoniae , topoisomerase IV seems to be the primary target of trovafloxacin.

antimicrobial agents and chemotherapy

Cloning and Nucleotide Sequence of the DNA Gyrase ( <i>gyrA</i> ) Gene from <i>Mycoplasma hominis</i> and Characterization of Quinolone-Resistant Mutants Selected In Vitro with Trovafloxacin

Cloning and Nucleotide Sequence of the DNA Gyrase ( gyrA ) Gene from Mycoplasma hominis and Characterization of Quinolone-Resistant Mutants Selected In Vitro with Trovafloxacin